LumiThera, Inc. Announces Creation of a Light-based Theranostic Approach to Treat Ocular Disease with Acquisition of Diopsys, Inc.

November 11, 2021
12:17 pm

LumiThera, Inc. Announces Creation of a Light-based Theranostic Approach to Treat Ocular Disease with Acquisition of Diopsys, Inc.

SEATTLE, Nov. 11, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced its entry into a definitive merger agreement with Diopsys, Inc.,…

Click here to view the original article.

Global, PRNewswire

Share this article

XTB CEO Wants Spot Crypto to Slash CFD Revenue Dominance From 95% to 70%

February 24, 2026

Is Zoom (ZM) Offering Value After A 79% Five Year Share Price Decline

February 24, 2026

Crypto platform Step Finance shutting down after $40 million theft

February 24, 2026

Is Rubrik (RBRK) Share Price Weakness Presenting A Long Term Opportunity?

February 24, 2026

Crypto executives push back on viral claim — TradingView News

February 24, 2026

QC Capital Announces Strategic Investment in My Pediatric Doctor to Expand Nationwide 24/7 Pediatric Urgent Care Telehealth Access

February 24, 2026

Is Perrigo (PRGO) Pricing Reflect The Recent Long Term Share Price Slide

February 24, 2026

Kraken brings crypto-style, 24/7 perpetuals trading for tokenized U.S. stocks

February 24, 2026